Modulation of immunoproteasome subunits by liposomal lipid A. (Q39985578)

16 September 2017

Modulation of immunoproteasome subunits by liposomal lipid A. (English)

1 reference

16 September 2017

1 reference

Nicholas J Steers

1

1 reference

16 September 2017

Carl R Alving

series ordinal

2

1 reference

16 September 2017

Mangala Rao

series ordinal

3

1 reference

16 September 2017

language of work or name

English

0 references

publication date

14 April 2008

1 reference

16 September 2017

11

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

16 September 2017

26

1 reference

16 September 2017

2849-2859

1 reference

16 September 2017

23

1 reference

Liposomes as carriers of antigens and adjuvants

16 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Lipid A and liposomes containing lipid A as antigens and adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Liposome-encapsulated antigens are processed in lysosomes, recycled, and presented to T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Proteasome inhibitors block the entry of liposome-encapsulated antigens into the classical MHC class I pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Human dendritic cells and macrophages exhibit different intracellular processing pathways for soluble and liposome-encapsulated antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Immunogenicity of liposomal malaria sporozoite antigen in monkeys: adjuvant effects of aluminium hydroxide and non-pyrogenic liposomal lipid A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Monophosphoryl lipid A enhances specific CTL induction by a soluble protein antigen entrapped in liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Immunostimulatory CpG motifs induce CTL responses to HIV type I oligomeric gp140 envelope protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Antibody and cytotoxic T-lymphocyte responses to a single liposome-associated peptide antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Selection of potent immunological adjuvants for vaccine construction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Phagocytosis of liposomes by macrophages: intracellular fate of liposomal malaria antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Peptide antigen production by the proteasome: complexity provides efficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

The 26S proteasome: a molecular machine designed for controlled proteolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Structure of 20S proteasome from yeast at 2.4 A resolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Visualization of peptides derived from liposome-encapsulated proteins in the trans-Golgi area of macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Immunoproteasomes shape immunodominance hierarchies of antiviral CD8(+) T cells at the levels of T cell repertoire and presentation of viral antigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Modulation of antigen processing and presentation by persistent virus infections and in tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Immunoproteasome assembly and antigen presentation in mice lacking both PA28alpha and PA28beta.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Pronounced up-regulation of the PA28alpha/beta proteasome regulator but little increase in the steady-state content of immunoproteasome during dendritic cell maturation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Differential expression regulation of the alpha and beta subunits of the PA28 proteasome activator in mature dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Liposomes as carriers for vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

A cytomegalovirus inhibitor of gamma interferon signaling controls immunoproteasome induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Inducible expression of Stat4 in dendritic cells and macrophages and its critical role in innate and adaptive immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

IFN-alpha beta-dependent, IFN-gamma secretion by bone marrow-derived macrophages controls an intracellular bacterial infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

Rates of Processing Determine the Immunogenicity of Immunoproteasome-Generated Epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.03.065

10.1016/J.VACCINE.2008.03.065

7 January 2021

Identifiers

DOI

1 reference

16 September 2017

1 reference